# Embed cachexia treatment in chemotherapy trials: weight, muscle and treatment delivery as co-primary endpoints

Source: https://onco.cc/ideas/idea-pdac-cachexia-trials-embedded-in-chemotherapy-trials/  
OnCo record `idea-pdac-cachexia-trials-embedded-in-chemotherapy-trials` (Idea). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Most people with pancreatic cancer lose muscle and weight in a way food alone cannot reverse, and that wasting is a common reason chemotherapy is cut or stopped. A 2024 trial showed an antibody against the hormone GDF-15 restored weight and activity in twelve weeks, a third of the patients having pancreatic cancer. The proposal is to test it inside the chemotherapy trials, not alongside them.

## Summary

Fearon's 2011 consensus defined cachexia as ongoing skeletal muscle loss not fully reversible by nutritional support, with weight loss over 5 percent (or over 2 percent with low body mass index or sarcopenia) as the diagnostic criterion and stages from pre-cachexia to refractory. Ponsegromab (Groarke 2024) in 187 patients with raised GDF-15 (32 percent pancreatic cancer) produced dose-dependent weight gain versus placebo of 1.22 to 2.81 kg at 12 weeks, with better appetite and measured physical activity at 400 mg and fewer adverse events than placebo. In pancreatic cancer specifically, cachexia and exocrine insufficiency (enzyme replacement reaching 21.7 percent of UK patients, Roberts 2019) determine whether patients receive and tolerate FOLFIRINOX-class regimens, yet cachexia trials are run in mixed-cancer populations with weight as the endpoint and chemotherapy trials exclude patients with significant weight loss. The proposal is a factorial or platform design in first-line pancreatic cancer: chemotherapy backbone with or without a GDF-15 antibody, with mandatory enzyme replacement and dietetic support in all arms, and co-primary endpoints of relative dose intensity delivered and lean mass at 12 weeks, with overall survival as the key secondary.

## Fields

- Kind: Idea
- Last checked: 2026-09-24
- Tags: pancreatic-evidence
- Hypothesis: Adding GDF-15 blockade to first-line chemotherapy in pancreatic cancer patients with cachexia or raised GDF-15 increases the relative dose intensity of chemotherapy delivered by 10 percentage points and preserves lean mass, and this translates into longer overall survival.
- Rationale: The mechanism is validated in humans, a third of the phase 2 population had pancreatic cancer, and treatment delivery is the variable that links wasting to survival.
- Proposed test: Randomised phase 2 or 3 in first-line metastatic or locally advanced disease, stratified by GDF-15 and weight loss, co-primary endpoints relative dose intensity and lean mass by CT at 12 weeks, overall survival key secondary; enzyme replacement and dietetic support protocolised in every arm.
- Maturity: early-clinical
- Actor: research

## Sources

- Groarke et al.: ponsegromab for cancer cachexia (NEJM 2024): https://europepmc.org/article/MED/39282907
- Fearon et al.: definition and classification of cancer cachexia (Lancet Oncol 2011): https://europepmc.org/article/MED/21296615
- ClinicalTrials.gov NCT05546476: https://clinicaltrials.gov/study/NCT05546476

## Connected records

- roadmaps: [Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question](https://onco.cc/roadmaps/pancreatic-roadmap/), [Supportive care and survivorship roadmap: making treatment bearable → proving it extends life → caring for tens of millions afterwards](https://onco.cc/roadmaps/survivorship-roadmap/)
- ideas: [Pancreatic enzyme replacement by default: prescribe at diagnosis, audit the rate, and run the trial that settles survival](https://onco.cc/ideas/idea-pdac-enzyme-replacement-prescribing-by-default/)
- cancers: [Metastatic pancreatic ductal adenocarcinoma](https://onco.cc/cancers/metastatic-pdac/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- fronts: [Diet, Exercise & Lifestyle](https://onco.cc/fronts/nutrition-lifestyle/), [Supportive Care & Survivorship](https://onco.cc/fronts/supportive-care/)
- drugs: [FOLFIRINOX / mFOLFIRINOX](https://onco.cc/drugs/folfirinox/), [Gemcitabine + nab-paclitaxel](https://onco.cc/drugs/gemcitabine-nab-paclitaxel/), [Ponsegromab](https://onco.cc/drugs/ponsegromab/)
- companies: [Pfizer (incl. Seagen)](https://onco.cc/companies/pfizer/)
- terms: [Performance status (ECOG, Karnofsky)](https://onco.cc/terms/performance-status/)
- bottlenecks: [Cachexia, toxicity and the limits of the patient](https://onco.cc/bottlenecks/b-cachexia-supportive/), [Older and multimorbid patients are excluded and undertreated](https://onco.cc/bottlenecks/b-aging-comorbidity/), [Trial design, endpoints and cost](https://onco.cc/bottlenecks/b-trial-design/)
- key papers: [Definition and classification of cancer cachexia: an international consensus](https://onco.cc/key-papers/paper-fearon-lancet-oncol/), [Enzyme replacement improves survival among patients with pancreatic cancer: Results of a population based study](https://onco.cc/key-papers/paper-roberts-pert-survival-pancreatic-cancer-pancreatology-2019/), [Ponsegromab for the Treatment of Cancer Cachexia](https://onco.cc/key-papers/paper-groarke-ponsegromab-cancer-cachexia-nejm-2024/)

---
JSON: https://onco.cc/api/v1/entities/idea-pdac-cachexia-trials-embedded-in-chemotherapy-trials.json